who we are
Angion is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries.
The Angion team is dedicated to bring new therapeutic options to patients. Currently our primary focus is chronic fibrotic conditions in the lung and kidney where effective treatments with more limited off-target toxicities are needed.
ANG-3070 clinical trials
If you wish to learn more about enrolling in our Phase 2 trial studying the safety and efficacy of ANG-3070 in patients with primary proteinuric kidney diseases, click here.
If you want to learn more about enrolling in our Phase 1b trial studying the safety, tolerability, and pharmacokinetics of ANG-3070 in patients with idiopathic pulmonary fibrosis (IPF), click here (coming soon!).
OUR LEAD CLINICAL ASSET
THE SCIENCE BEHIND
ANG-3070 is a highly-selective, oral tyrosine kinase receptor inhibitor (TKI) designed to target key pro-fibrotic tyrosine kinases in order to inhibit activity in fibrotic pathways while limiting off-target inhibition.*
ANG-3070 primarily targets DDR1/2 and PDGFRα/β. DDR1/2 are thought responsible for mediating the activation of myelofibroblasts during fibrosis. PDGFRα/β mediate inflammation and fibrosis.
*ANG-3070 is currently being studied in clinical trials to determine safety and efficacy. It is not yet approved for use by any regulatory agency globally.